ClinicalTrials.gg
Not yet recruitingNCT07846488Updated Sep 29, 2026

Combined Acupuncture-Based Therapy for Rehabilitation After Ischemic Stroke

An interventional study of Electro-Field Acupuncture and Electro-Acupuncture in Ischemic Stroke, Hemiplegia and Neurogenic Dysphagia, sponsored by National Hospital of Acupuncture, Vietnam. Not yet recruiting at 1 site in Vietnam. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by National Hospital of Acupuncture, Vietnam · Not applicable, Interventional, and Treatment

Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
440
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing cerebrolysin in Ischemic Stroke — 5 open to participants now, 5 under way, none of them phase 3. cerebrolysin · Ischemic Stroke.

Planned enrollment
2nd of 12
440 · median 92
Started
2026
with 1 other
No phase
2 of 12
2 open now
Registered
12th of 12
by date
Lead sponsor
1 of 12
National Hospital of Acupuncture, Vietnam

Among the 12 studies testing cerebrolysin in Ischemic Stroke, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2026, is one of 2 with no phase, and was the 12th registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

5 of the 12 studies testing cerebrolysin in Ischemic Stroke are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About cerebrolysin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing cerebrolysin in Ischemic Stroke, or all of them as a file.
02

Study summary

Objective: To assess the therapeutic efficacy of combined electroacupuncture (or electric field acupuncture), hydroacupuncture (Cerebrolysin or B-complex vitamins), and acupressure massage in restoring motor function and treating dysphagia in post-acute ischemic stroke patients, while evaluating safety profiles and prognostic factors associated with clinical outcomes.

Interventions:

Participants will be randomly assigned to one of four treatment arms:

Group 1: Electric field acupuncture + Cerebrolysin Acupoint injection + acupressure massage Group 2: Electric field acupuncture + B-complex vitamin Acupoint injection + acupressure massage Group 3: Electroacupuncture + Cerebrolysin Acupoint injection + acupressure massage Group 4: Electroacupuncture + B-complex vitamin Acupoint injection + acupressure massage The intervention duration is 30 days.

03

Conditions studied

  • Ischemic Stroke
  • Hemiplegia
  • Neurogenic Dysphagia

Keywords

  • Electro - acupuncture
  • Acupressure
  • Acupoint injection
  • Motor Rehabilitation
  • neurogenic dysphagia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Patients were eligible for inclusion in the study if they met all of the following criteria:

  • Aged 18 years or older, regardless of sex and occupation.
  • Diagnosed with post-acute ischemic stroke.
  • Stabilized cardiovascular, respiratory, and neurological conditions, as well as vital signs following the acute phase.
  • Hemiplegia/Hemiparesis (motor deficit on one side of the body).
  • Fully conscious and capable of cooperating with clinicians, with a (MMSE) score ≥ 20.
  • Presence of dysphagia, confirmed by a Mann Assessment of Swallowing Ability (MASA) score ≤ 177.
  • National Institutes of Health Stroke Scale (NIHSS) score ≥ 5.
  • Clinical diagnosis of ischemic stroke confirmed by brain magnetic resonance imaging (MRI) showing ischemic lesions.
  • Patients and/or their legal representatives voluntarily provided written to participate in the study.

Exclusion Criteria:

  • Cerebral venous infarction, hemorrhagic transformation of cerebral infarction.
  • Stage 3-4 heart failure, cerebral vascular malformations, cerebral air embolism, (COPD).
  • Respiratory failure requiring endotracheal intubation, impaired consciousness.
  • Concurrent systemic or neuropsychiatric conditions: tuberculosis, psychiatric disorders, /AIDS, epilepsy, esophageal stricture, pyloric stenosis.
  • Patients who have not received Cerebrolysin treatment during the acute phase.
  • Non-cooperative patients, participants who fail to complete the full course of treatment, or patients whose clinical symptoms progressively worsen to a life-threatening level during the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
440 participants (estimated)

Study arms

  • Experimental
    Evaluation of the effect on motor function recovery in post-acute stroke patients

    Device: Electro-Field Acupuncture · Device: Electro-Acupuncture · Drug: Cerebrolysin · Drug: B complex vitamin · Other: Acupressure Massage

  • Experimental
    Evaluation of the therapeutic effect on dysphagia in post-acute stroke patients

    Device: Electro-Field Acupuncture · Device: Electro-Acupuncture · Drug: Cerebrolysin · Drug: B complex vitamin · Other: Acupressure Massage

Interventions

  • DeviceElectro-Field Acupuncture

    Electro-field acupuncture will be administered according to the standardized study procedure using predefined acupuncture points and electrical stimulation parameters.

  • DeviceElectro-Acupuncture

    Electro-acupuncture will be administered according to the standardized study procedure using predefined acupuncture points and electrical stimulation parameters.

  • Cerebrolysin will be administered by acupoint injection according to the standardized study protocol.

  • DrugB complex vitamin

    B complex vitamin will be administered by acupoint injection according to the standardized study protocol.

  • OtherAcupressure Massage

    Acupressure massage will be administered as background therapy to all participants according to the standardized treatment protocol.

06

What researchers measure

Primary outcomes

  1. Change in Fugl-Meyer Assessment score for motor function in post-acute stroke patients

    Motor function will be assessed using the Fugl-Meyer Assessment (FMA). The FMA motor function score ranges from 0 to 100, with higher scores indicating better motor function. The primary outcome is the change in FMA motor function score from baseline (Day 0) to Day 15 and Day 30.

    Time frame: Baseline (Day 0) to Day 15 and Day 30

Secondary outcomes

  1. Change in Gugging Swallowing Screen (GUSS) score for swallow function in post-acute stroke patients

    Dysphagia will be assessed using the Gugging Swallowing Screen (GUSS), a 24-item clinical swallowing assessment. The total GUSS score ranges from 0 to 20, with a maximum score of 20. Higher scores indicate better swallowing function and less severe dysphagia, while lower scores indicate greater swallowing impairment. The change in GUSS score from baseline to Day 15 and Day 30 will be evaluated.

    Time frame: Baseline (Day 0) to Day 15 and Day 30

07

Study locations

1 site
  • National Hospital of Acupuncture
    Hanoi, Hanoi 10000, Vietnam
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — No. Individual participant data will not be shared outside the research team.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jun 2028, 18 months later.

Of 573 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 18 months is below that.

Counting every sponsor, half of 654 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2026
First posted
Sep 29, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Jun 30, 2028
CompletionEst.
Dec 31, 2028
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07846488
Lead sponsor
National Hospital of Acupuncture, Vietnam
Responsible party
MSc.MD Nguyen Thi Ngoc Linh (Head of the Scientific Research Department, National Hospital of Acupuncture, Vietnam) — Principal investigator
First posted
Sep 29, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Jun 30, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Sep 29, 2026

Study contacts

Ngoc Linh Thi Nguyen, MD, MSc
Contact
nguyenthingoclinh.bs249@gmail.com
+84358961018
Thanh Hoa Thi Phi, MD, PhD
Contact
Drthanhhoa@hotmail.com
+84968217057
Thanh Van Tran, MD, Associate Professor
principal investigator · National Hospital of Acupuncture

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cerebrolysin

Start the discussion